Ceftobiprole - Wikipedia, the free encyclopedia
Ceftobiprole (Zeftera / Zevtera) is a next generation (5th generation) cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus, penicillin ...
Cephalosporin - Wikipedia, the free encyclopedia
Ceftobiprole has been described as "fifth generation", [14] [15] though acceptance for this terminology is not universal. Ceftobiprole (and the soluble prodrug medocaril) are on the FDA ...
Activity of ceftobiprole against community-associated methicillin ...
1: Diagn Microbiol Infect Dis. 2007 Dec;59(4):463-6. Epub 2007 Oct 29. Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates ...
New Data Show Ceftobiprole As Effective As Combination Therapy In ...
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., announced that the investigational antibiotic ceftobiprole was as effective as commonly used combination therapy ...
Ceftobiprole: a new option for treatment of skin and soft-tissue ...
1: Clin Infect Dis. 2008 Mar 1;46(5):656-8. Comment on: Clin Infect Dis. 2008 Mar 1;46(5):647-55. Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to ...
Basilea Pharmaceutica - Home
The company`s diversified portfolio includes two commercialized drugs (alitretinoin, ceftobiprole), one investigational drug in phase III (isavuconazole) as well as innovative ...
J&J files Ceftobiprole in Switzerland - FiercePharma
A Johnson & Johnson unit has filed for Swiss approval to sell ceftobiprole, marketed in partnership with developer Basilea Pharmaceutical, as a treatment for diabetic foot ...
BASILEA REPORTS 92% CLINICAL CURE RATES FOR CEFTOBIPROLE ...
Ceftobiprole is the first anti-MRSA broad-spectrum cephalosporin to demonstrate efficacy in a large clinical trial in patients infected with staphylococcal infections, including ...
Basilea Pharmaceutica - Development - Ceftobiprole
Ceftobiprole belongs to a well accepted class of antibacterial agents known as cephalosporins that are used to treat serious life-threatening infections caused by Gram ...
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin ...
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Information provided by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
